NTMed

Developing materials combining electrical exogenous stimulus, antimicrobial efficacy, and safety for wound healing.

Health Tech & Life Sciences
Active
Seed Raanana, Israel Founded 2020
LinkedIn
Last updated 2026-07-20
Total raised
$800K
Last: Undisclosed Round 2020-01
Stage
Seed
Founded
2020
Headcount
4
HQ
Raanana, Israel
Sector
Health Tech & Life Sciences

About

NTMed is developing the first and only materials combining electrical exogenous stimulus enhancing healing processes, best antimicrobial efficacy, and highest safety profile. Chronic, non-healing wounds impact millions, generating overall cost projections exceeding $100 billion. Wound healing is a complex, dynamic cellular-based process supported by a myriad of cellular events that must be tightly coordinated to efficiently repair damaged tissue. Electric fields at wounds play a major role in wound healing and regenerative processes, with possible mechanisms involving regulation of cell migration, cell differentiation, and tissue growth.

Funding history · 1 round · $800K total

2019-12
Seed $800K

Q&A

What is NTMed's primary focus?
NTMed is developing materials that combine electrical exogenous stimulus, antimicrobial efficacy, and a high safety profile to enhance wound healing processes.
When was NTMed founded?
NTMed was founded in January 2020.
What is the total amount of funding NTMed has raised to date?
NTMed has raised a total of $800,000 USD.
What is NTMed's primary sector classification?
NTMed's primary sector is Health Tech & Life Sciences.
What business models does NTMed utilize?
NTMed utilizes a B2B2C business model.
What is the product stage of NTMed's offerings?
NTMed's products are currently in the R&D stage.

Team · 3

Valery Diamant
Founder · Co-Founder
Marat Lerner
Founder · Co-Founder
Gideon Meiry
Founder · Co-Founder

Sectors & technology

Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyBiomaterials & Tissue Engineering
Technologies
Materials & SubstancesBiologicals
Target customers
Healthcare & Life SciencesLife SciencesPharmaceuticals
Business model
B2B2C

Highlights

1 PatentsVerified

Tags

nanotechnologypharmaceuticalsbiomaterials
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)